Hewmun Lau
Principal at Broadview Ventures
Greater Boston
Overview
Work Experience
Principal
2019 - Current
Principal
2019
Responsible for the day-to-day investment activities at Broadview Ventures, including identification and screening of new opportunities, due diligence, negotiation of deal structure, and portfolio company board involvement. Broadview is a mission-driven fund whose primary investment goal is to improve human health in the areas of cardiovascular disease and stroke. With 37 such investments since 2008, Broadview has considerable experience in the seed/early-stage space.
Broadview Ventures invests in businesses that focus on the development of technology solutions in cardiovascular and neurovascular diseases.
Board Observer
2020
Antag Therapeutics is a Copenhagen-based preclinical stage biotechnology company focused on developing therapies for dietary-related metabolic diseases. The company’s current lead therapy is a glucose-dependent insulinotropic peptide receptor (GIPR) antagonist for inducing weight loss in obese patients with Type-2 Diabetes.
Board Observer
2020
Basking Biosciences, Inc. is developing the first reversible thrombolytic therapy for Acute Ischemic Stroke (AIS). Basking is focused on exploiting the properties of RNA biology to develop aptamers with high affinity and specificity against proteins involved in coagulation and hemostasis.
Board Observer
2020 - 2021
Renovacor is a preclinical stage biotechnology company whose mission is to develop improved therapies for genetically derived cardiovascular diseases. The company is currently developing a gene therapy for a rare, familial form of dilated cardiomyopathy due to mutation in the BAG3 gene.
Director of Corporate Development
2018 - 2019
Associate Director, New Product Planning and Business Development
2017 - 2018
Senior Manager, Commercial Analytics - ONIVYDE
2015 - 2017
- Play key role in building commercial analytic capabilities for Merrimack's first product launch in oncology - Analytics lead for Northeast and Southeast Regions, act as strategic thought partner with Field to develop actionable business recommendations in order to drive ONIVYDE adoption - Supported cross-functional teams in Marketing, Product Availability and Market Access, Commercial IT, among others, in critical business decision-making, Communicate key findings to a broad range of key stakeholders
Merrimack is a biopharmaceutical company that designs and develops medicines to treat cancer.
Raised $432,013,000.00 from Hercules Capital.
Senior Consultant (Life Sciences Practice)
2012 - 2015
Strategic life science consultant with experience across multiple therapeutic areas and project types, including: - Commercial opportunity assessments and forecasting - New product launch planning - Competitive assessments - BD&L opportunity assessments Skills include primary and secondary market research, forecasting, project management
Guidehouse is a global provider of consulting services with a focus on driving cross-market advancements.
Raised $860,577.00 from NYSERDA, NYSERDA, NYSERDA and NYSERDA.
Summer Associate (Life Sciences Practice)
2011 - 2011
Guidehouse is a global provider of consulting services with a focus on driving cross-market advancements.
Raised $860,577.00 from NYSERDA, NYSERDA, NYSERDA and NYSERDA.
Summer Intern
2010 - 2010
Business Development
Research Associate
2007 - 2009
Laboratory of Genetic Neuropharmacology
McLean Hospital is providing a range of quality, cost effective, and mental health services.
Raised $13,500,000.00 from MassAITC, Rare Impact Fund and National Institute of Mental Health.